SHEL.UK

3,448.5

-0.1%↓

BP

548.7

+0.49%↑

REN

29.94

+0.67%↑

SDR

572

+0.09%↑

PSON

1,006

+1.23%↑

SHEL.UK

3,448.5

-0.1%↓

BP

548.7

+0.49%↑

REN

29.94

+0.67%↑

SDR

572

+0.09%↑

PSON

1,006

+1.23%↑

SHEL.UK

3,448.5

-0.1%↓

BP

548.7

+0.49%↑

REN

29.94

+0.67%↑

SDR

572

+0.09%↑

PSON

1,006

+1.23%↑

SHEL.UK

3,448.5

-0.1%↓

BP

548.7

+0.49%↑

REN

29.94

+0.67%↑

SDR

572

+0.09%↑

PSON

1,006

+1.23%↑

SHEL.UK

3,448.5

-0.1%↓

BP

548.7

+0.49%↑

REN

29.94

+0.67%↑

SDR

572

+0.09%↑

PSON

1,006

+1.23%↑

Search

Smith & Nephew PLC

Ouvert

1,255.5 1.58

Résumé

Variation du prix de l'action

24h

Actuel

Min

1235

Max

1258.5

Chiffres clés

By Trading Economics

Revenu

47M

342M

Ventes

318M

3.3B

P/E

Moyenne du Secteur

22.991

66.822

BPA

0.429

Rendement du dividende

3.13

Marge bénéficiaire

10.36

Employés

17,000

EBITDA

162M

886M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+17.65% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

3.13%

3.56%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-606M

11B

Ouverture précédente

1253.92

Clôture précédente

1255.5

Smith & Nephew PLC Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 mars 2026, 22:42 UTC

Résultats

Prudential PLC 2025 Adjusted Operating Profit Rises

17 mars 2026, 21:40 UTC

Résultats

Alimentation Couche-Tard Records Higher Profit, Revenue in 3Q

17 mars 2026, 23:56 UTC

Market Talk

BHP's Next CEO Likely to Build On Existing Strategic Direction -- Market Talk

17 mars 2026, 23:46 UTC

Market Talk

Nikkei May Rise After Recent Selloffs -- Market Talk

17 mars 2026, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 mars 2026, 23:42 UTC

Market Talk

RBA's Return to Policy Tightening Will Work -- Market Talk

17 mars 2026, 23:38 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Before FOMC Decision -- Market Talk

17 mars 2026, 23:24 UTC

Market Talk

Global Energy Roundup: Market Talk

17 mars 2026, 23:24 UTC

Market Talk

New Woodside CEO Seen as Low-Risk Appointment -- Market Talk

17 mars 2026, 22:22 UTC

Market Talk

BHP Hands Reins to Growth-Focused Executive -- Market Talk

17 mars 2026, 22:20 UTC

Résultats

Prudential PLC 2025 New Business Profit $2.78B Vs. $2.46B >2378.HK

17 mars 2026, 22:20 UTC

Résultats

Prudential PLC 2025 Adj Operating Profit $3.31B Vs. $3.13B >2378.HK

17 mars 2026, 22:07 UTC

Résultats

Nvidia Says It Is Restarting Production of AI Chips for Sale in China -- WSJ

17 mars 2026, 22:05 UTC

Résultats

ZTO Express (Cayman): Frank Zhen Wei to Resign From Board

17 mars 2026, 22:04 UTC

Résultats

ZTO Express (Cayman): Board Approves Repurchase of Up to $1.5B of Shares Over Next 24 Months >ZTO

17 mars 2026, 22:03 UTC

Résultats

ZTO Express (Cayman) Raises Semiannual Dividend to 39c Vs. 30c >ZTO

17 mars 2026, 22:01 UTC

Résultats

ZTO Express (Cayman) 4Q Adj EPS 47c >ZTO

17 mars 2026, 22:01 UTC

Résultats

ZTO Express (Cayman) 4Q Rev $2.08B >ZTO

17 mars 2026, 22:01 UTC

Résultats

ZTO Express (Cayman) 4Q EPS 47c >ZTO

17 mars 2026, 21:26 UTC

Résultats

Oklo Stock Wavers After Earnings, but the Nuclear Start-Up Has Good News -- Barrons.com

17 mars 2026, 21:09 UTC

Résultats

Couche-Tard: 12 Company-Operated Stores Acquired During 3Q

17 mars 2026, 21:08 UTC

Résultats

Couche-Tard 3Q Consolidated Same-Store Merchandise Revenue Up 2% >ATD.T

17 mars 2026, 21:08 UTC

Résultats

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 mars 2026, 21:07 UTC

Résultats

Couche-Tard 3Q EPS 82c >ATD.T

17 mars 2026, 21:06 UTC

Résultats

Couche-Tard 3Q Rev $21.8B >ATD.T

17 mars 2026, 21:05 UTC

Résultats

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 mars 2026, 21:05 UTC

Résultats

Couche-Tard 3Q Rev $21.8B >ATD.T

17 mars 2026, 21:05 UTC

Résultats

Couche-Tard 3Q EPS 82c >ATD.T

17 mars 2026, 21:05 UTC

Résultats

Couche-Tard 3Q Net $757.2M >ATD.T

17 mars 2026, 20:50 UTC

Market Talk
Principaux Événements d'Actualité

Energy & Utilities Roundup: Market Talk

Comparaison

Variation de prix

Smith & Nephew PLC prévision

Objectif de Prix

By TipRanks

17.65% hausse

Prévisions sur 12 Mois

Moyen 1,460.57 GBX  17.65%

Haut 1,700 GBX

Bas 1,300 GBX

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

7 ratings

4

Achat

3

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat